Abstract
We report a newly emerged SARS-CoV-2 Omicron lineage, named FY.4, that has two unique mutations; spike:Y451H and ORF3a:P42L. FY.4 emergence has coincided with increased SARS-CoV-2 cases in coastal Kenya, April-May 2023. We demonstrate the value of continued SARS-CoV-2 genomic surveillance in the post-acute pandemic era in understanding new COVID-19 outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by (i) New Variant Assessment Programme (NVAP), The New Variant Assessment Platform (NVAP) is a UK Health Security Agency programme funded by the UK Department of Health and Social Care (DHSC) as a global initiative to strengthen genomic surveillance for pandemic preparedness and response to emerging and priority infectious diseases, National Institute for Health and Care Research (NIHR) (project references 17/63/82 and 16/136/33) using UK Aid from the UK Government to support global health research, The UK Foreign, Commonwealth and Development Office (FCDO) and (ii) The Wellcome, UK (grant# 220985/Z/20/Z and 226002/A/22/Z). The views expressed in this publication are those of the author(s) and not necessarily those of NIHR, the Department of Health and Social Care, or the Foreign Commonwealth and Development Office, the Africa-CDC, WHO-Afro, ASLM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The whole genome sequencing study protocol was reviewed and approved by the Scientific and Ethics Review Committee (SERU) residing at the Kenya Medical Research Institute (KEMRI) headquarters in Nairobi (SERU # 4035).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Genome sequences generates in this study are available on GISAID. Generated genomes are listed in the gisaid_supplemental_table_epi_set_230627zw.pdf. The, the dataset and analysis scripts used are available in Havard Dataverse at https://doi.org/10.7910/DVN/ZMGR5P.
